"This is testing a whole new paradigm, a whole new approach, towards treating atherosclerosis," because anti-inflammatory drugs are not now a therapy of choice, says Michael Lauer, director of the Division of Cardiovascular Sciences at NHLBI.
- Health Topics
- Health Education
- The Science
- Grants and Training
- News and Events
- About NHLBI